Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Inavolisib in combination with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer

Condition

Breast

Cancer

6 February 2026

-

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended inavolisib, in combination with palbociclib and fulvestrant, for inclusion on the MOH List of Subsidised Drugs for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine therapy. The decision was based on the unfavourable cost effectiveness compared with palbociclib plus fulvestrant at the proposed price, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for inavolisib are provided in the Annex.

Guidance-Inavolisib in combination with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer (6 Feb 2026) (opens in new tab)

PES_Inavolisib in combination with palbociclib and fulvestrant for treating PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (6 Feb 2026) (opens in new tab)